Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-18, Stock:NVS, The news for the past five days is as follows:
2018-04-11: NEWS1: Novartis’s Valuation and Analysts’ Recommendations on April 11.NEWS2: Incyte Expected to Report Robust Revenue Growth in Fiscal 2018.NEWS3: Novartis’s Stock Performance following the AveXis Agreement.NEWS4: This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous.NEWS5: This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous.NEWS6: Novartis Enters Agreement to Acquire AveXis.NEWS7: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS8: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS9: Alexion's Deal Discipline Sure Beats a Previous Disaster.NEWS10: This Little-Known Company Should Have Gilead&apos;s and Celgene&apos;s Investors Nervous.NEWS11: Why CASI Pharmaceuticals Stock Rose Last Week.NEWS12: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS13: The Swiss Stock Market Dropped On Syria Concerns.NEWS14: The Swiss Stock Market Dropped On Syria Concerns.
2018-04-12: NEWS1: Why One Drug Flop Tanked Incyte's Stock.NEWS2: Why One Drug Flop Tanked Incyte's Stock.NEWS3: Why One Drug Flop Tanked Incyte&apos;s Stock.NEWS4: GlaxoSmithKline Buys Novartis’s Stake in Joint Venture.NEWS5: The Swiss Stock Market Climbed As Syria Concerns Ease.NEWS6: The Swiss Stock Market Climbed As Syria Concerns Ease.NEWS7: Incyte Has Diversified Its Revenues across Multiple Product Lines.
2018-04-13: NEWS1: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS2: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS3: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV&apos;s Drugs Succeed in Phase III.NEWS4: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS5: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS6: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS7: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS8: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS9: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS10: Rigel Pharmaceuticals&apos; (RIGL) Stock Gains 16%: Here&apos;s Why.NEWS11: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS12: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS13: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS14: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS15: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS16: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS17: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS18: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS19: These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years.NEWS20: Same as the old boss — Novan makes interim CEO permanent.NEWS21: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.
2018-04-16: NEWS1: How Did Biogen Miss AveXis?.NEWS2: How Did Biogen Miss AveXis?.NEWS3: Did Novartis Overpay for AveXis?.NEWS4: Did Novartis Overpay for AveXis?.NEWS5: What Novartis Bought in AveXis.NEWS6: What Novartis Bought in AveXis.NEWS7: Did Novartis Overpay for AveXis?.NEWS8: How Did Biogen Miss AveXis?.NEWS9: What Novartis Bought in AveXis.NEWS10: Gilead (GILD) Presents Encouraging Data on NASH Therapies.NEWS11: Gilead (GILD) Presents Encouraging Data on NASH Therapies.NEWS12: VXUS, NSRGY, NVS, BTI: ETF Inflow Alert.NEWS13: VXUS, NSRGY, NVS, BTI: ETF Inflow Alert.NEWS14: The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte.NEWS15: The Swiss Stock Market Dropped As NestlÃ© Goes Ex-Dividend.NEWS16: The Swiss Stock Market Dropped As NestlÃ© Goes Ex-Dividend.NEWS17: NVS: Entresto Preserves Kidney Function In Diabetic Patients With Chronic HF.NEWS18: NVS: Entresto Preserves Kidney Function In Diabetic Patients With Chronic HF.
2018-04-17: NEWS1: 5 Biotech IPOs to Watch in April.NEWS2: 5 Biotech IPOs to Watch in April.NEWS3: Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria.NEWS4: Novartis’s Innovative Medicines Segment in 1Q18.NEWS5: What's in Store for Novartis (NVS) This Earnings Season?.NEWS6: What's in Store for Novartis (NVS) This Earnings Season?.NEWS7: Novartis’s 1Q18: Analysts Expect Revenue Growth.NEWS8: What&apos;s in Store for Novartis (NVS) This Earnings Season?.NEWS9: Expectations from Novartis’s 1Q18 Earnings.NEWS10: Risankizumab Could Be AbbVie’s Long-Term Growth Driver.NEWS11: The Swiss Stock Market Rebounded As Syria Concerns Relax.NEWS12: The Swiss Stock Market Rebounded As Syria Concerns Relax.NEWS13: Novartis tender offer for AveXis commences.NEWS14: Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts.NEWS15: Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts.

Answer: Decrease